Georg Mn Behrens

List of Publications by Year
in descending order

98 papers	8,326 citations	117625 34 h-index	53230 85 g-index
115 all docs	115 docs citations	115 times ranked	12134 citing authors

#	Article	IF	Citations
1	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. Clinical Gastroenterology and Hepatology, 2023, 21, 713-722.e3.	4.4	9
2	Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. HIV Medicine, 2022, 23, 558-563.	2.2	47
3	Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2. Peritoneal Dialysis International, 2022, 42, 100-101.	2.3	10
4	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell, 2022, 185, 447-456.e11.	28.9	736
5	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Frontiers in Immunology, 2022, 13, 863039.	4.8	10
6	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. HIV Medicine, 2022, 23, 849-858.	2.2	57
7	Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects. Biomedicines, 2022, 10, 693.	3.2	1
8	Close to Zero, but Not Zero: What Is an Acceptable HIV Transmission Risk Through Breastfeeding?. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, e42-e42.	2.1	3
9	Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination. Emerging Infectious Diseases, 2022, 28, 743-750.	4.3	18
10	Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process. HIV Medicine, 2022, 23, 639-649.	2.2	3
11	SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. Cell Reports, 2022, 39, 110754.	6.4	5
12	Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. Lancet Infectious Diseases, The, 2022, 22, 766-767.	9.1	79
13	SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study. BMC Infectious Diseases, 2022, 22, 403.	2.9	10
14	Self-reported Tinnitus and Vertigo or Dizziness in a Cohort of Adult Long COVID Patients. Frontiers in Neurology, 2022, 13, 884002.	2.4	13
15	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host and Microbe, 2022, 30, 1103-1111.e6.	11.0	38
16	Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2. , 2022, , .		0
17	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cellular and Molecular Immunology, 2021, 18, 936-944.	10.5	98
18	Beyond Viral Suppression. Open Forum Infectious Diseases, 2021, 8, ofab044.	0.9	0

#	Article	IF	Citations
19	COVID-19 immune signatures reveal stable antiviral TÂcell function despite declining humoral responses. Immunity, 2021, 54, 340-354.e6.	14.3	177
20	Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in NaÃ¯ve HIV-1â€“Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, e146-e149.	2.1	0
21	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. Clinical Infectious Diseases, 2021, 73, 2000-2008.	5.8	30
22	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	12.8	67
23	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Reports, 2021, 36, 109415.	6.4	206
24	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 2021, 27, 1525-1529.	30.7	363
25	Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cellular and Molecular Immunology, 2021, 18, 2455-2456.	10.5	35
26	Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. EBioMedicine, 2021, 70, 103524.	6.1	53
27	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Reports, 2021, 37, 109825.	6.4	73
28	SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. Lancet, The, 2021, 398, 1041-1042.	13.7	24
29	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 342	9.1	1,430
30	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. Cellular and Molecular Immunology, 2021, 18, 2673-2675.	10.5	25
31	Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. Cellular and Molecular Immunology, 2021, 18, 2557-2559.	10.5	41
32	Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?. Frontiers in Medicine, 2021, 8, 770381.	2.6	14
33	Improving HIV-related care through eHealth. Lancet HIV,the, 2020, 7, e8-e10.	4.7	6
34	Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. Infectious Diseases and Therapy, 2020, 9, 837-849.	4.0	34
35	The Loss of HLA-F/KIR3DS1 Ligation Is Mediated by Hemoglobin Peptides. International Journal of Molecular Sciences, 2020, 21, 8012.	4.1	4
36	Clinical management of ageing people living with HIV in Europe: the view of the care providers. Infection, 2020, 48, 497-506.	4.7	7

#	Article	IF	Citations
37	Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. Infection, 2020, 48, 631-634.	4.7	69
38	Plea for multitargeted interventions for severe COVID-19. Lancet Infectious Diseases, The, 2020, 20, 1122-1123.	9.1	18
39	Ability to Monitor National Responses to the HIV Epidemic â€œBeyond Viral Suppressionâ€: Findings From Six European Countries. Frontiers in Public Health, 2020, 8, 36.	2.7	2
40	1269. Cohort Profile: The Translational Platform HIV (TP-HIV), a Multicenter Cohort Project in Germany. Open Forum Infectious Diseases, 2019, 6, S456-S457.	0.9	0
41	Pediatric Healthcare Utilization in a Large Cohort of Refugee Children Entering Western Europe During the Migrant Crisis. International Journal of Environmental Research and Public Health, 2019, 16, 4415.	2.6	8
42	Reorienting health systems to care for people with HIV beyond viral suppression. Lancet HIV,the, 2019, 6, e869-e877.	4.7	57
43	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e86-e94.	2.1	53
44	Prevalence and Types of Anemia in a Large Refugee Cohort in Western Europe in 2015. Journal of Immigrant and Minority Health, 2018, 20, 1332-1338.	1.6	13
45	Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica, 2018, 103, 857-864.	3.5	27
46	Molecular Epidemiology of the HIV Epidemic in Three German Metropolitan Regions â€“ Cologne/Bonn, Munich and Hannover, 1999â€“2016. Scientific Reports, 2018, 8, 6799.	3.3	25
47	Healthcare Utilization in a Large Cohort of Asylum Seekers Entering Western Europe in 2015. International Journal of Environmental Research and Public Health, 2018, 15, 2163.	2.6	24
48	Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8⁺ T cell proliferation. European Journal of Immunology, 2018, 48, 2042-2054.	2.9	11
49	Pregnancy Related Health Care Needs in Refugeesâ€”A Current Three Center Experience in Europe. International Journal of Environmental Research and Public Health, 2018, 15, 1934.	2.6	27
50	Tuberculosis Specific Interferon-Gamma Production in a Current Refugee Cohort in Western Europe. International Journal of Environmental Research and Public Health, 2018, 15, 1263.	2.6	6
51	Seroprevalence of antibodies and antigens against hepatitis Aâ€“E viruses in refugees and asylum seekers in Germany in 2015. European Journal of Gastroenterology and Hepatology, 2017, 29, 939-945.	1.6	35
52	Measles, Rubella and Varicella IgG Seroprevalence in a Large Refugee Cohort in Germany in 2015: A Cross-Sectional Study. Infectious Diseases and Therapy, 2017, 6, 487-496.	4.0	23
53	Herpes simplex virus 1 interferes with autophagy of murine dendritic cells and impairs their ability to stimulate CD8⁺ T lymphocytes. European Journal of Immunology, 2017, 47, 1819-1834.	2.9	26
54	Norovirus outbreaks in german refugee camps in 2015. Zeitschrift Fur Gastroenterologie, 2017, 55, 997-1003.	0.5	9

#	Article	IF	Citations
55	Tetanus and diphtheria immunity in refugees in Europe in 2015. Infection, 2017, 45, 157-164.	4.7	35
56	The incidence of first-line antiretroviral treatment changes and related factors among HIV-infected sex workers in Nairobi, Kenya. Pan African Medical Journal, 2017, 28, 7.	0.8	7
57	Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs. Pan African Medical Journal, 2016, 25, 14.	0.8	6
58	Systematic Review of the Current Literature on Structured Treatment Interruptions in HIV-infected Patients Receiving Antiretroviral Therapyâ€"Implications for Future HIV Cure Trials. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
59	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
60	Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015. Infection, 2016, 44, 781-787.	4.7	57
61	An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PLoS ONE, 2016, 11, e0155406.	2.5	5
62	Inhibition of Autophagic Flux by Salinomycin Results in Anti-Cancer Effect in Hepatocellular Carcinoma Cells. PLoS ONE, 2014, 9, e95970.	2.5	51
63	Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-NaÃ¯ve HIV-1â€"Infected Patients with HIV-1 RNA â‰¤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis. AIDS Patient Care and STDs, 2014, 28, 168-175.	2.5	27
64	Thymidine Analogues Suppress Autophagy and Adipogenesis in Cultured Adipocytes. Antimicrobial Agents and Chemotherapy, 2013, 57, 543-551.	3.2	18
65	Toll-Like Receptorâ€"2 Agonistâ€"Allergen Coupling Efficiently Redirects Th2 Cell Responses and Inhibits Allergic Airway Eosinophilia. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 852-863.	2.9	14
66	Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation. Aids, 2012, 26, 1995-2006.	2.2	44
67	Switching to Tenofovir/Emtricitabine from Abacavir/ Lamivudine in HIV-Infected Adults with Raised Cholesterol: Effect on Lipid Profiles. Antiviral Therapy, 2012, 17, 1011-1020.	1.0	45
68	Abacavir and myocardial infarctions. Aids, 2011, 25, 2043-2045.	2.2	4
69	Abacavir and cardiovascular risk. Current Opinion in Infectious Diseases, 2010, 23, 9-14.	3.1	33
70	The synthetic TLR2 agonist BPPcysMPEG leads to efficient crossâ€priming against coâ€administered and linked antigens. European Journal of Immunology, 2010, 40, 1272-1283.	2.9	37
71	FcÎ³ receptorâ€mediated antigen uptake by lung DC contributes to allergic airway hyperâ€responsiveness and inflammation. European Journal of Immunology, 2010, 40, 1284-1295.	2.9	16
72	Impaired Lung Dendritic Cell Migration and T Cell Stimulation Induced by Immunostimulatory Oligonucleotides Contribute to Reduced Allergic Airway Inflammation. Journal of Immunology, 2009, 183, 3443-3453.	0.8	10

#	Article	IF	Citations
73	Contribution of Direct and Cross-Presentation to CTL Immunity against Herpes Simplex Virus 1. Journal of Immunology, 2009, 182, 283-292.	0.8	33
74	Impact of boostering for the strength of asthma parameters and dendritic cell numbers in a C57BL/6 model of allergic airway inflammation. Experimental and Toxicologic Pathology, 2008, 60, 425-434.	2.1	7
75	Treatment options for lipodystrophy in HIV-positive patients. Expert Opinion on Pharmacotherapy, 2008, 9, 39-52.	1.8	5
76	A database of naturally occurring human urinary peptides and proteins for use in clinical applications. Nature Precedings, 2007, , .	0.1	0
77	Relationship of Mitochondrial DNA Depletion and Respiratory Chain Activity in Preadipocytes treated with Nucleoside Reverse Transcriptase Inhibitors. Antiviral Therapy, 2007, 12, 205-216.	1.0	27
78	Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nature Immunology, 2006, 7, 165-172.	14.5	308
79	The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10729-10734.	7.1	357
80	Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. New England Journal of Medicine, 2005, 352, 1721-1722.	27.0	12
81	Helper Requirements for Generation of Effector CTL to Islet Î² Cell Antigens. Journal of Immunology, 2004, 172, 5420-5426.	0.8	56
82	Helper T cells, dendritic cells and CTL Immunity. Immunology and Cell Biology, 2004, 82, 84-90.	2.3	101
83	Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunological Reviews, 2004, 199, 9-26.	6.0	641
84	Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. Aids, 2003, 17, S149-S154.	2.2	35
85	Pathogenesis of the HAART-Associated Metabolic Syndrome. , 2003, 40, 83-96.		2
86	Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1â€“infected patients with lipodystrophy. Journal of Clinical Investigation, 2002, 110, 1319-1327.	8.2	57
87	Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1â€“infected patients with lipodystrophy. Journal of Clinical Investigation, 2002, 110, 1319-1327.	8.2	30
88	Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. Aids, 2001, 15, 2407-2414.	2.2	212
89	CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. European Journal of Immunology, 2001, 31, 3121-3126.	2.9	410
90	Immune Reconstitution Syndromes in Human Immunodeficiency Virus Infection Following Effective Antiretroviral Therapy. Immunobiology, 2000, 202, 186-193.	1.9	59

#	Article	IF	Citations
91	Lipodystrophy Syndrome in HIV Infection. Drug Safety, 2000, 23, 57-76.	3.2	96
92	Lessons from lipodystrophy:LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy. Aids, 2000, 14, 1854-1855.	2.2	15
93	ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet, The, 1999, 354, 76.	13.7	38
94	Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. Aids, 1999, 13, F63-F70.	2.2	454
95	Lipid Evaluation in HIV-1-Positive Patients Treated with Protease Inhibitors. Antiviral Therapy, 1999, 4, 163-170.	1.0	33
96	Highly active antiretroviral therapy. Lancet, The, 1998, 351, 1057-1058.	13.7	30
97	Vascular complications associated with use of HIV protease inhibitors. Lancet, The, 1998, 351, 1958.	13.7	201
98	Healthcare Workers' Perceptions and Medically Approved COVID-19 Infection Risk: Understanding the Mental Health Dimension of the Pandemic. A German Hospital Case Study. Frontiers in Public Health, 0, 10, .	2.7	4